EBA
DNA icon

Eagle Bay Advisors’s Ginkgo Bioworks DNA Stock Holding History

Eagle Bay Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-48
Closed -$471 – 346
2024
Q4 		$471 Hold
48
– – ﹤0.01% 963
2024
Q3 		$391 Sell
48
-1
-2% -$10 ﹤0.01% 1317
2024
Q2 		$654 Hold
49
– – ﹤0.01% 953
2024
Q1 		$2.27K Hold
49
– – ﹤0.01% 865
2023
Q4 		$3.31K Hold
49
– – ﹤0.01% 692
2023
Q3 		$3.54K Hold
49
– – ﹤0.01% 711
2023
Q2 		$3.64K Hold
49
– – ﹤0.01% 709
2023
Q1 		$2.6K Hold
49
– – ﹤0.01% 733
2022
Q4 		$3.31K Buy
49
+4
+9% +$368 ﹤0.01% 714
2022
Q3 		$6K Hold
45
– – ﹤0.01% 656
2022
Q2 		$4.31K Buy
+45
New +$5.49K ﹤0.01% 745
2022
Q1 		– Sell
-23
Closed -$8K – 468
2021
Q4 		$8K Buy
23
+10
+77% +$4.75K 0.01% 721
2021
Q3 		$8K Buy
+13
New +$6.33K ﹤0.01% 763

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Eagle Bay Advisors's DNA Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Ginkgo Bioworks (DNA) in Q1 2025, closing a stake of 48 shares — an estimated $471 sold.

Eagle Bay Advisors first reported a position in DNA in Q3 2021 and held it in 13 quarters. The position peaked at $8K in Q4 2021. 167 funds tracked by Wall St. Rank hold DNA as of Q1 2025.

  • Eagle Bay Advisors reported no remaining Ginkgo Bioworks position as of Q1 2025 after selling out during the quarter.
  • Eagle Bay Advisors sold 48 Ginkgo Bioworks shares in Q1 2025, an estimated $471.
  • Eagle Bay Advisors first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 13 quarters.
  • Eagle Bay Advisors's Ginkgo Bioworks position peaked at $8K in Q4 2021.
  • 167 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.